The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells (original) (raw)

AI-generated Abstract

The study investigates the role of the novel AML stem cell-associated antigen, CLL-1, in distinguishing between normal and leukemic stem cells in patients with acute myeloid leukemia (AML). Despite current chemotherapy treatments, the prognosis remains poor due to leukemic relapses, emphasizing the need for targeted therapies that can specifically identify and treat leukemic stem cells while sparing normal stem cells. The authors present data supporting that CLL-1 can effectively identify a subpopulation of CD34+CD38- cells associated with minimal residual disease (MRD), which may be crucial for improving diagnostic and therapeutic strategies for AML.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact